Vertex News

In the first case of its kind, the results include one of the planet's most expensive pills, huge sales projections for a drug company and windfalls for executives who sold stock in the glow of enthusiastic news releases about the drug.

The number of shares sold short in Dendreon , Gilead Sciences , Illumina , Onyx Pharmaceuticals and VIVUS grew somewhat between the April 15 and April 30 settlement dates.

Keep track of the stocks that matter to you. Help yourself with the Fool's FREE and easy new watchlist service today.

Pharmaceuticals Incorporated today announced that Vertex will webcast its presentations at the Bank of America Healthcare conference on Tuesday, May 14, 2013 at 3:40 PM PT and at the Sanford Bernstein Strategic Decisions conference on Wednesday, May 29, 2013 at 2:00 PM ET.

RnRMarketResearch.com adds new market research report "OpportunityAnalyzer: Cystic Fibrosis Therapeutics - Opportunity Analysis and Forecasts to 2017" to its store.

The biotechs, particularly the mega big-cap stocks, have been stellar performers in this robust bull run -- driven by expectations of strong quarterly results and sustainable accelerating growth rates.

The stock price of Vertex Pharmaceuticals spiked up 3% in early Wednesday trading after the company announced its Q1 2013 financials the previous evening, beating analyst expectations on revenue and net earnings.

Recently, shares of Catalyst Pharmaceutical Partners and Vertex Pharmaceuticals spiked dramatically upward, drawing the attention of many traders and investors.

Vertex Pharmaceuticals issued its quarterly earnings data on Tuesday. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of by $0.09, AnalystRatings.Net reports.

Vertex Pharmaceuticals Inc. swung to a first-quarter loss as sales of its hepatitis C drug plummeted from a year earlier and the company wrote down the value of one of its pipeline drugs.

Vertex Pharmaceuticals Inc. was up in the first few minutes of after-hours trading following its report that revenue for the first three months of the year was $328 million, down 25 percent from the same period last year, but beating analyst expectations of $308 million.

The Rumor : Shares of Sarepta Therapeutics rose in early trading Thursday on unconfirmed market chatter of a potential bid for the maker of Eteplirsen, which is designed to treat Duchenne muscular dystrophy.

Vertex Pharmaceuticals : "I think the stock could go much higher. I say own Vertex.

I am skeptical of the US equity markets right now. With the flash crash and immediate recovery caused by one comment of a hacked Twitter account on Tuesday, I think any prudent investor should be.